Study narrows search for genes placing men at increased risk for prostate cancer

August 17, 2004

August 18, Phoenix, AZ--Scientists at the Translational Genomics Research Institute (TGen), Johns Hopkins Medical Institutions, the National Institutes of Health, The University of Michigan and five other research institutes world-wide announced today the findings from the largest study of the genetics of prostate cancer undertaken to date. Results have zeroed in on three different regions of the genome containing genes that may make men more vulnerable to this common cancer. Prostate cancer is the second-leading cause of cancer death in US men. The findings appear in the August 18 issue of the Journal of the National Cancer Institute.

The researchers are currently scouring those genome regions, culled from more than 400 cancer-prone families, to identify specifically which genes lead to increased prostate cancer susceptibility.

"This study will help us predict better who is at the highest risk for this disease," says the paper's lead author, Dr. Elizabeth Gillanders, a scientist at the National Institutes of Health in Bethesda, MD. "If we could identify men with susceptibility genes, we can target our surveillance to them and identify their cancers much earlier. Early-stage treatment is far more beneficial in prostate cancer," she says.

In addition, she noted, prostate cancers in men who possess susceptibility genes tend to be more aggressive--and more often fatal--than prostate cancers in men who are not genetically prone to the disease.

"This study focuses and intensifies the hunt for genes that increase a man's risk of prostate cancer," says the paper's senior author, Dr. Jeffrey M. Trent, Scientific Director of TGen in Phoenix, Arizona. "We needed this sort of massive study in order to have the power to target important genome regions."

"The difference between this paper and previous work on the genetics of prostate cancer is the number of families studied," says Dr. William B. Isaacs, of the Johns Hopkins University in Baltimore, MD, principal investigator for the project. "There has been much confusion and difficulty in trying to figure out where we should be looking for these genes." Today's paper reports on data from approximately 2,000 individuals from over 400 families.

"The large number of prostate cancer families utilized in this study allowed us to overcome the challenges we have faced in this field for the past few years," says Dr. Jianfeng Xu, one of the lead authors on the paper and a researcher at Wake Forest University School of Medicine. "This study shows that hereditary prostate cancer genes exist and demonstrates that by working together, teams of researchers are able to locate these genes. These results give us a renewed confidence in our search for prostate cancer genes."

"These are exciting times," says Dr. John Carpten, Senior Investigator and Director of TGen's Prostate Cancer Research Program. "Prostate cancer has turned out to be a formidable enemy to all men. We look forward to maturing this research in order to help discover new genetic diagnostic tools for prostate cancer susceptibility in hopes of one day winning the war against this awful disease."

The study was the result of an increasing trend in genomic research: an extensive international collaboration of scientists from multiple institutions. Large-scale collaborative studies like this are increasingly common in complex disorders that have a huge impact on public health, such as cancer, heart disease, diabetes, and mental health disorders like autism. Complex disorders involve more than one gene--often many--and a host of environmental factors, which makes them particularly hard to investigate.

Dr. Richard N. Atkins, President & CEO of the National Prostate Cancer Coalition, noted: "We applaud public and private investments that lead to new discoveries to save lives. Sadly, prostate cancer remains the most common occurring malignancy in America - other than skin cancer, and we still know far too little about how to prevent it, detect it, and treat it."
Research institutions involved include the National Human Genome Research Institute at the National Institutes of Health in Bethesda, MD; the Wake Forest University School of Medicine in Winston-Salem, NC; the University of Umea in Sweden; the Fox Chase Cancer Center in Philadelphia, PA; the Johns Hopkins Medical Institutions in Baltimore, MD; the University of Michigan in Ann Arbor; and the University of Tampere and Tampere University Hospital in Finland.

Background information on prostate cancer
Prostate cancer is cancer of the gland that makes part of a man's seminal fluid. The prostate is located in front of the rectum and under the bladder. The disease usually progresses slowly and may not require treatment for many years, but prostate cancer was responsible for the deaths of almost 31,000 US men in 2001. It is the second-leading cause of cancer death in US men (after lung cancer.) The American Cancer Society estimates that more than 230,000 cases of prostate cancer will be diagnosed in US men in 2004; 98% of these men will live for at least five more years.

About TGen
TGen is a not-for-profit research institute whose primary mission is to make and translate genomic discoveries into advances in human health. Translational genomics research employs innovative advances arising from the Human Genome Project and applies them to the development of diagnostics, prognostics, and therapies for cancer, neurological disorders, diabetes and other complex diseases. For more information, visit For more information about prostate cancer awareness and advocacy visit The National Prostate Cancer Coalition

The Translational Genomics Research Institute

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to